Avastin helps cervical cancer patients
Avastin and chemotherapy added four months of survival among advanced cervical cancer patients. Medpage Today reported Friday that the study, published in the New England Journal of Medicine, showed median overall survival was 17 months with Avastin vs. 13.3 using only chemotherapy. Adding Avastin to platinum-based or nonplatinum therapy did not have a significant impact on results.
“Cervical cancer patients are often mothers with minor children. This is a major advance and clinical benefit to those patients," Memorial Sloan-Kettering Cancer Center's Carol Aghajaman told Medpage.